Bejelentkezés Regisztrálj ingyen

Inhibrx Intézményi tulajdon

Mi az Inhibrx Intézményi tulajdon?

A Intézményi tulajdon az Inhibrx, Inc. - 80.27%

Mi a Intézményi tulajdon meghatározása?



Az intézményi tulajdonság a kölcsönös vagy nyugdíjpénztárak, biztosítótársaságok, befektetési vállalkozások, alapítványok vagy más, a mások nevében pénzeszközöket kezelő nagyvállalatok tulajdonában lévő, rendelkezésre álló állomány összege.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Intézményi tulajdon a Health Care szektor a NASDAQ-on cégekben a Inhibrx -hoz képest

Mit csinál Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

intézményi tulajdon -hoz hasonló cégek Inhibrx